In 2019, the global age-standardized death rate for Down syndrome was around 0.3 per 100,000 population. At that time, the death rate for Down syndrome was highest in Tropical Latin America, with around 0.7 deaths per 100,000 population. The most common cause of death for adults and children with Down syndrome is respiratory infection. This statistic shows the age-standardized death rate for Down syndrome worldwide in 1990 and 2019, by region.

Model 2. Paternal Age Random-walk (CAR). OpenBUGS code and data that can be used to repeat the analyses for Model 2. (TXT 2 kb)

Legacy unique identifier: P00440

In 2019, the global age-standardized death rate for Down syndrome was around 0.3 per 100,000 population. The most common cause of death for adults and children with Down syndrome is respiratory infection. This statistic shows the age-standardized death rate for Down syndrome worldwide in 1990 and 2019, by gender.

Background. Downs syndrome (DS) is the commonest of the congenital genetic defects. Its incidence has been rising in recent years for unknown reasons. Objective. Investigate the relationship of DS to substance- and cannabinoid- exposure; and causality.

Methods. Observational ecological population-based epidemiological study 1986-2016. Analysis performed January 2020. Geotemporospatial and causal inference analysis.

Participants: Patients were diagnosed with DS and reported to state based registries; collated nationally. Data source: annual reports of National Birth Defects Prevention Network of Centres for Disease Control.

Exposures: Drug exposure was taken from the National Survey of Drug Use and Health (NSDUH) conducted annually by Substance Abuse and Mental Health Services Administration. Nationally representative sample 67,000 participants annually. Drug exposures: cigarette consumption, alcohol abuse, analgesic/opioid abuse, cocaine use and last month cannabis use. Ethnicity and median household income: US Census Bureau. Maternal age of childbearing: CDC births registries. Cannabinoid concentrations: Drug Enforcement Agency seizures.

Results. NSDUH report 74.1% mean annual response rate. All other data was population-wide. DS rate (DSR) was noted to be rising over time, cannabis use, and cannabis-use quintile. In the optimal geospatial model lagged to four years terms including Δ9-tetrahydrocannabinol and cannabigerol were significant (from β-est.=4189.96 (95%C.I. 1924.74, 6455.17), P=2.9x10-4). Ethnicity, income, and maternal age covariates were not significant. DSR in states where cannabis was not illegal was higher than elsewhere (β-est.=2.160 (1.5, 2.82), R.R.=1.81 (1.51, 2.16), P=4.7x10-10). In inverse probability-weighted mixed models terms including cannabinoids were significant (from β-estimate=18.82 (16.82, 20.82), P

Conclusions. Our data show that the association between DSR and substance- and cannabinoid- exposure is robust to multivariable geotemporospatial adjustment, implicate particularly cannabigerol and Δ9-tetrahydrocannabinol, and fulfil causal crietria. Cannabis legalization was associated with elevated DSR’s. These findings are consistent with those from Hawaii, Colorado, Canada and Australia and concordant with several cellular mechanisms. Given that the cannabis industry is presently in a rapid growth-commercialization phase the present findings linking cannabis use with megabase scale genotoxicity suggest unrecognized DS risk factors, are of public health importance and suggest that re-focussing the cannabis debate on multigenerational and intergenerational health concerns is prudent.

Prenatal Screening Market Outlook

In 2023, the global prenatal screening market size was valued at approximately USD 5 billion and is projected to reach around USD 10 billion by 2032, growing at a compound annual growth rate (CAGR) of around 8%. The market is primarily driven by increasing awareness and advancements in prenatal screening technologies, leading to early and accurate detection of fetal anomalies. Additionally, the rising prevalence of genetic disorders, coupled with the growing demand for non-invasive testing methods, is expected to fuel further growth. The global healthcare industry’s emphasis on preventive care and the increasing maternal age are significant contributors to this upward trend in the prenatal screening market.

One of the foremost growth factors for the prenatal screening market is the technological advancements in non-invasive prenatal testing (NIPT). NIPT has transformed prenatal screening by offering a highly accurate and risk-free method of detecting chromosomal abnormalities in the fetus. It’s a preferable choice for expecting mothers, particularly those in high-risk categories, as it eliminates the need for invasive sampling techniques like amniocentesis, which carry potential risks for both the mother and the fetus. The continuous improvements in sequencing technologies, coupled with increased availability and affordability, have expanded the accessibility of NIPT, driving the market growth substantially.

Moreover, the rising maternal age worldwide is another critical factor propelling the prenatal screening market. As more women choose to start families later in life, the risk of chromosomal abnormalities rises, thereby increasing the demand for prenatal screening. Older maternal age is associated with a higher likelihood of chromosomal aneuploidies such as Down syndrome, spurring the need for reliable and early detection methods. Healthcare providers advocate prenatal screenings as a standard practice for expectant mothers over the age of 35, which indirectly boosts the market. The simultaneous increase in global birth rates also adds to the demand for comprehensive prenatal screenings.

The growing awareness and emphasis on early diagnosis and preventive healthcare measures further bolster the market. With the support of government initiatives and healthcare policies aimed at improving maternal and fetal health outcomes, more expectant mothers are opting for prenatal screenings. These screenings allow for the early detection and management of potential chromosomal and genetic disorders, providing critical information for making informed healthcare decisions. Education campaigns and counseling services regarding the benefits and availability of prenatal screening are enhancing public perception and acceptance, contributing significantly to market expansion.

Regionally, North America holds the largest share of the prenatal screening market due to the high adoption rate of advanced screening technologies and supportive healthcare infrastructure. The presence of major market players and the availability of comprehensive insurance coverage for prenatal tests drive market growth in this region. Europe follows closely, with countries like Germany, France, and the UK showing strong adoption rates due to increasing awareness and government support. The Asia Pacific region is expected to witness the highest growth rate due to an increasing population base and improving healthcare infrastructure. China and India, with their large populations, offer significant potential for market expansion. The market in Latin America and the Middle East & Africa is also growing steadily, albeit at a slower pace, due to improvements in healthcare access and rising awareness.

Test Type Analysis

The test type segment of the prenatal screening market includes non-invasive prenatal testing (NIPT), maternal serum screening, ultrasound, and others. Non-invasive prenatal testing (NIPT) is the fastest-growing segment within this category. It is favored for its high accuracy and safety, as it involves analyzing cell-free fetal DNA circulating in the maternal blood. Its ability to detect common chromosomal abnormalities like trisomy 21, 18, and 13 with high sensitivity and specificity has made it a popular choice among healthcare providers and expectant parents. The ease of the testing process and reduced risk compared to invasive methods are key factors driving the growth of NIPT in the prenatal screening market.

Maternal serum screening is another significant segment in the prenatal screening market. This involves a blood test to evaluate the levels of

Non-Invasive Prenatal Testing Kit Market Outlook

The global market size for Non-Invasive Prenatal Testing (NIPT) kits was valued at approximately USD 3.4 billion in 2023 and is anticipated to reach nearly USD 9.8 billion by 2032, showcasing a robust CAGR of 12.5% during the forecast period. This impressive growth is driven by several factors including advancements in diagnostic technology, increasing awareness among expectant parents, and the escalating incidences of chromosomal abnormalities.

One of the primary growth factors for the NIPT kit market is the rising prevalence of genetic disorders like Down syndrome, Edwards syndrome, and Patau syndrome among newborns. With an increasing number of older women opting for pregnancies, the risk of chromosomal abnormalities has surged, thereby driving the demand for non-invasive prenatal testing. Additionally, advancements in cell-free DNA technology have significantly improved the accuracy and reliability of these tests, further propelling market growth.

Another pivotal growth factor is the growing awareness and acceptance of non-invasive prenatal testing among healthcare providers and expectant parents. The non-invasive nature of these tests ensures that they pose minimal risk to both the mother and the fetus, making them a preferred option over invasive methods like amniocentesis. Furthermore, increasing educational campaigns and endorsements from healthcare organizations are enhancing the adoption rates of NIPT kits globally.

The market is also experiencing growth due to the continuous innovations and improvements in prenatal testing technologies. Companies are investing heavily in research and development to introduce advanced testing kits that offer quicker results, higher accuracy, and comprehensive genetic screening capabilities. This has led to the development of more sophisticated instruments and software that streamline the testing process and improve diagnostic outcomes.

Regionally, North America dominates the NIPT kit market due to its advanced healthcare infrastructure, high awareness levels, and supportive government policies. However, the Asia Pacific region is expected to exhibit the highest growth rate during the forecast period, driven by increasing healthcare expenditure, rising awareness, and the growing number of late maternal age pregnancies. Europe also holds a significant share, owing to advancements in healthcare technologies and increased acceptance of prenatal screening methods.

Product Type Analysis

In the NIPT kit market, the product type segment is classified into consumables, instruments, and software. Consumables, which include reagents, test kits, and other supplies used in the testing process, form a substantial part of the market. Due to the recurrent need for these items with each test conducted, consumables are expected to maintain a significant market share. The constant demand from laboratories and hospitals contributes significantly to the revenue generated in this segment.

Instruments used in NIPT, such as sequencers and analyzers, form another crucial segment. With continuous advancements in technology, newer and more efficient instruments are introduced, enhancing the accuracy and speed of prenatal tests. This segment, although requiring a higher initial investment, promises substantial growth due to the increasing adoption of advanced diagnostic tools in hospitals and diagnostic centers. The integration of AI and machine learning in these instruments further adds to their efficacy, making them indispensable in prenatal diagnostics.

Software solutions form the backbone of NIPT, as they are essential for analyzing the vast amounts of genetic data generated during testing. Robust software solutions enable precise interpretation of test results, ensuring accurate detection of genetic anomalies. Companies are focusing on developing advanced software that can handle complex genetic data and provide user-friendly interfaces for healthcare professionals. This segment is expected to grow significantly as software innovations continue to improve data analysis and reporting capabilities in prenatal testing.

Report Scope

Global Non-invasive prenatal testing market size was $1,567.9 million in 2022. Non-invasive prenatal testing Industry's Compound Annual Growth Rate will be 18.9% from 2023 to 2030. Factors Affecting Non-Invasive Prenatal Testing market growth.

The increasing prevalence of chromosomal abnormalities with increasing maternal age is anticipated to drive the demand in the global non-invasive prenatal testing market. In addition, rising incidences of down syndrome are driving the growth of the global market. Furthermore, an increase in the number of kids with chromosomal disorders and improved diagnostic imaging technology provide an opportunity for the target market. However, the high cost of these tests to its relatively low affordability may hamper the growth of the global market. What is Non-Invasive Prenatal Testing?

Non-invasive prenatal testing is a DNA-based blood test that is used to assess the risk of genetic disorders in the developing fetus. This is done to see if a person suffers from down syndrome, Patau syndrome, Edwards syndrome, and others.

Legacy unique identifier: P00448

Legacy unique identifier: P00434

Legacy unique identifier: P00439